![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Demonstrates Comparable Efficacy and Favorable
Tolerability to Efavirenz/Emtricitabine/Tenofovir DF in Patients with Adherence <95% and <90%
|
|
|
Reported by Jules Levin
IDSA Oct 17-21 2012 San Diego
E DeJesus1, W Robbins2, F Bredeek3, P Shalit4, K White5, H Liu5, L Dau5, E Quirk5, and D Piontkowsky5
1Orlando Immunology Center, Orlando, FL; 2Value Health MD, LLC, Orlando, FL; 3Metropolis Medical Group, San Francisco, CA;
4Tribal Med, Seattle, WA; 5Gilead Sciences Inc., Foster City, CA
![IDSA1.gif](../images/102912/102912-1/IDSA1.gif)
![IDSA2.gif](../images/102912/102912-1/IDSA2.gif)
![IDSA3.gif](../images/102912/102912-1/IDSA3.gif)
![IDSA4.gif](../images/102912/102912-1/IDSA4.gif)
![IDSA5.gif](../images/102912/102912-1/IDSA5.gif)
![IDSA6.gif](../images/102912/102912-1/IDSA6.gif)
![IDSA7.gif](../images/102912/102912-1/IDSA7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|